Guardant Health Inc(GH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:30 PM ET (Korea 9/11 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.5 | Insider Own | 4.02% | Shs Outstand | 133.6M | Perf Week | -2.47% |
| Market Cap | 21.34B | Forward P/E | - | EPS next Y | 40.29% | Insider Trans | -14.14% | Shs Float | 128.8M | Perf Month | -3.67% |
| Enterprise Value | 21.98B | PEG | - | EPS next Q | -0.75 | Inst Own | 100.85% | Short Float | 8.69% | Perf Quarter | 21.68% |
| Income | -0.45B | P/S | 18.04 | EPS this Y | 3.47% | Inst Trans | -1.99% | Short Ratio | 4.46 | Perf Half Y | 80.65% |
| Sales | 1.18B | P/B | - | EPS next 5Y | 70.97% | ROA | -27.95% | Short Interest | 11.19M | Perf YTD | 55.7% |
| Book/sh | -1.67 | P/C | 20.26 | EPS past 3/5Y | 19.67% -4.99% | ROE | - | 52W High | -9.94% ($176.58) | Perf Year | 181.12% |
| Cash/sh | 7.85 | P/FCF | - | Sales past 3/5Y | 29.75% 27.92% | ROIC | -31.35% | 52W Low | 197.81% ($53.40) | Perf 3Y | 371.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -4.6% | Gross Margin | 65.01% | Volatility(W/M) | 5.55% 4.64% | Perf 5Y | 23.19% |
| Dividend TTM | - | EV/Sales | 18.58 | Sales Y/Y TTM | 42.74% | Oper. Margin | -39.7% | ATR (14) | 8 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.71 | EPS Q/Q | -12.34% | Profit Margin | -38.33% | RSI (14) | 47.44 | Recom | 1.34 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.03 | Sales Q/Q | 44.33% | SMA20 | -2.47% ($163.06) | Beta | 1.59 | Target Price | $199.44 |
| Payout | - | Debt/Eq | - | Earnings | 2026/7/30 | SMA50 | -0.68% ($160.12) | Rel Volume | 0.42 | Prev Close | $162.78 |
| Employees | 2506 | LT Debt/Eq | - | EPS/Sales Surpr. | -18.14% 6.6% | SMA200 | 34.41% ($118.32) | Avg Volume(3M) | 2.51M | Price | $159.03 |
| IPO | 2018/10/4 | Option/Short | Yes/Yes | Trades | 15411 | Volume | 1,048,663 | Change | -2.3% |
Company
GH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A precision diagnostics company that offers blood-based cancer genomic testing. Its core technology is liquid biopsy, which analyzes cancer-related genetic mutations from blood samples, and it provides cancer diagnostics to help guide treatment choices as well as early cancer screening tests. It is one of the leading companies in the liquid biopsy-based cancer diagnostics space.
Over the past 1 year, on the higher side
10% below its 1-year high.
GH has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +3.5% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +371.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 100.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
HELX 0.09%
EKG 0.06%
GNOM 0.06%
LFSC 0.06%
GDOC 0.05%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
RSP 98.6B
USHY 28.5B
FBND 28.3B
SDY 21.3B
DGRW 17.1BIt ranks #4 in the industry
Based on market cap of $21B.
GH $21B PER -
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is GH?
GH belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of GH?
The market cap of GH is approximately $21.3B, ranking 587 within its sector.
What is the 52-week high and low for GH?
GH has recorded a 52-week high of $176.58 and a low of $53.40.
